Romark to seek EUA for antiviral compound to treat COVID-19

14 April 2021

Privately-held Romark Laboratories has announced initial results from a Phase III trial of its oral investigational antiviral compound NT-300 (nitazoxanide extended-release tablets, 300mg) as a treatment for people aged 12 and older with COVID-19.

In the analysis of the primary endpoint for all evaluable patients, median time to sustained response was similar for subjects treated with NT-300 compared with placebo, at approximately 13 days. The median time to sustained response for a sub-group of evaluable patients with mild disease was reduced by 3.1 days with NT-300.

However, in looking at a key secondary endpoint, NT-300 reduced progression to severe disease in all evaluable patients by 85% compared with placebo. Only one person in the treatment arm progressed to severe COVID-19 disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK